Sixfold Bioscience

Delivering RNA therapies.

sixfold.bio

HQ: London, England, United Kingdom

11-50

Healthcare

Company research

Public company, workplace, funding, and market signals

Updated Aug 16, 2026

Overview

Sixfold Bioscience is a London-based biotech company building AI/computation-driven RNA delivery systems. Its primary product/platform is Mergo®, a programmable RNA tag and delivery platform designed to direct RNA therapeutics to previously untargetable tissues beyond the liver.

Primary product

Mergo® RNA delivery platform

Founded

2017

Headquarters

White City / London, United Kingdom

Team size

11-25

Industry

Biotechnology

Sub-industry

RNA therapeutics / oligonucleotide delivery / biotech platform

Offices

Translation & Innovation Hub, 84 Wood Ln, London W12 7SL, United Kingdom

White City Innovation District, London, United Kingdom

Business model

B2B licensing

collaboration / partnership

platform-enabled drug discovery

Funding

Stage

seed

Total raised

$10.5M

Latest round

Seed · Dec 2021

Latest amount

$10.5M

Grant

Jul 2024 · UKRI

Seed

Dec 2021

$10.5M

Non-dilutive funding / grant

Nov 2020 · UKRI Future Leaders Fellowship

People & investors

Leadership

Dr Anna Perdrix Rosell

Co-CEO + Founder

Dr George Foot

Co-CEO + Founder

Dr Tina Caroline Flatau

Chief Business Officer

Søren Ottosen, Ph.D.

VP of Research

Allison Morgan BSc

VP of Development (fractional)

David Ellam

CFO (fractional)

Neil Lawrence

Scientific Advisory Board member

David Lines

Computational lead / head of machine learning team

Founders

Dr. Anna Perdrix Rosell

Co-Founder, Co-CEO

Dr. George Foot

Co-Founder, Co-CEO

Investors

Lombard Street Ventures

Work & culture

The company describes itself as unconventional, collaborative, diverse, and focused on solving hard problems; it emphasizes a highly motivated team of engineers, builders, scientists, and operators.

Product & market

Pricing

Not publicly disclosed; likely enterprise collaboration and licensing model for platform access and therapeutic development partnerships.

Differentiators

—Designed to solve RNA delivery beyond the liver
—Mergo® is a programmable RNA tag approach rather than conventional encapsulation
—Uses AI/ML and automated chemistry to generate and screen large chemical design spaces
—Claims a manufacturable library of >100,000 machine-learning-generated Mergo constructs
—Combines biology-inspired delivery discovery with high-throughput experimentation

Technology

AI/ML

Bayesian optimization

machine learning-generated libraries

laboratory automation

high-throughput screening

design of experiments (DoE)

advanced chemistry

computational biology

Competitors

Genedit

TriSalus Life Sciences

Scholar Rock

Slingshot Biosciences

Aligned Bio

Halozyme

Lyra Therapeutics

Scale & contact

Estimated revenue

Unknown publicly; third-party estimates range around $3.4M annually, but this is not company-disclosed.

Estimated monthly visits

1.7K

Traffic estimate as of Jun 2026

Signals & risks

Other

Aug 2024

Companies House filing shows registration of charge 106877840001, indicating secured borrowing / financing activity rather than a negative event; later satisfied on 2024-10-14.

Source